SCHEDULE 13G: T. Rowe Price Associates Discloses 5.4% Stake in Quest Diagnostics Inc.
Schedule 13G Filing
T. Rowe Price Associates, Inc. has filed a Schedule 13G, revealing a beneficial ownership of 5.4% of Quest Diagnostics Inc.'s common stock as of March 31, 2025.
Summary
- T. Rowe Price Associates, Inc., an investment adviser based in Baltimore, MD, has filed a Schedule 13G with the SEC.
- The filing indicates that T. Rowe Price Associates, Inc. beneficially owns 5,995,335 shares of common stock in Quest Diagnostics Inc.
- This ownership represents 5.4% of the total class of Quest Diagnostics Inc. common stock.
- The shares are held with sole voting power over 5,753,218 shares and sole dispositive power over 5,973,144 shares.
- The filing date for the event requiring this statement was March 31, 2025.
Sentiment
Score: 5
Explanation: The document is a factual disclosure of an ownership stake, which is neutral in sentiment regarding the company's performance. The presence of a significant institutional investor can be viewed positively by some, but the filing itself does not convey explicit sentiment.
Future Outlook
This document is a disclosure of beneficial ownership and does not contain forward-looking statements or guidance from Quest Diagnostics Inc. or T. Rowe Price Associates, Inc. regarding the issuer's future performance.
Industry Context
This filing indicates a significant institutional investment in Quest Diagnostics, a major player in the diagnostic information services industry. Such disclosures are common for large asset managers and reflect their portfolio allocations within the healthcare sector.
Stakeholder Impact
- Shareholders: The disclosure of a significant stake by a reputable investment adviser like T. Rowe Price Associates, Inc. may be viewed as a vote of confidence in Quest Diagnostics Inc., potentially influencing investor sentiment positively.
Key Dates
| Date | Description |
|---|---|
| 03/31/2025 | Date of event which requires the filing of this statement, indicating the beneficial ownership stake. |
| 05/14/2025 | Date the Schedule 13G statement was signed by T. Rowe Price Associates, Inc. |
Keywords
Quest Diagnostics, T. Rowe Price Associates, Schedule 13G, Beneficial Ownership, Common Stock, Institutional Investor, SEC Filing, Investment Adviser, Healthcare Diagnostics
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.